Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis

pharmafocusasiaNovember 26, 2018

Tag: Primary Sclerosing Cholangitis , FDA , Orphan Drug , Pliant Therapeutics

PharmaSources Customer Service